Xspray Pharma Q3: Exciting Times Ahead
Research Note
2020-11-23
07:20
Redeye reiterates its positive view and Base case of SEK 200 per share following Xspray’s Q3 report. The report did not include any significant surprises. In this note, we briefly comment on financials and highlight important milestones during the period.
LS
Ludvig Svensson
Disclosures and disclaimers